Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-O-Demethylpenclomedine is a synthetic small molecule and the principal alkylating metabolite of penclomedine, a multichlorinated alpha-picoline derivative. It belongs to the polyhalopyridines class, characterized by a pyridine ring substituted with multiple halogen atoms. The compound acts as an antitumor agent through its highly reactive alkylating properties. After activation in the liver via free radical formation, it is transported to tumor cells where it forms DNA adducts and induces interstrand crosslinking through its chloro moieties. This leads to DNA damage and inhibition of cancer cell proliferation. Preclinical studies have shown activity against glioblastoma and breast tumors with lower neurotoxicity compared to penclomedine[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-O-Demethylpenclomedine.